Association of rs13429458 and rs12478601 Single Nucleotide Polymorphisms of THADA Gene with Polycystic Ovary Syndrome

Leila Naserpoor, M.Sc.1*, Rahil Jannatifar, Ph.D.1, Kambiz Roshanaei, M.D., Ph.D.2, Mohadeseh Khoshandam, M.Sc.1, Naser Kallhor, M.Sc.3

1. Department of Reproductive Biology, Academic Center for Education, Culture and Research, Qom Branch, Qom, Iran
2. Department of Biology, Faculty of Science, Islamic Azad University, Qom, Iran
3. Department of Mesenchymal Stem Cells, Academic Center for Education, Culture and Research, Qom Branch, Qom, Iran

Abstract

Background: It is thought that genetic factors are influential in the etiology of polycystic ovarian syndrome (PCOS), the most frequent endocrinological disorder of females in their reproductive age. This study was carried out to elucidate the association of rs13429458 and rs12478601 single nucleotide polymorphisms (SNPs) of the THADA gene and the risk of the PCOS among a population of Iranian female patients.

Materials and Methods: This case-control study contains 66 infertile women with PCOS (patient group) and 44 healthy women without PCOS (control group) that referred to the IVF Unit of the Infertility Research Center of the Academic Center for Education, Culture and Research (ACECR). The polymerase chain reaction (PCR) was utilized to amplify genome DNA as well as direct sequencing to determine SNPs. The THADA rs12478601 and rs13429458 genotypes were consequently examined with amplification refractory mutation system-PCR (ARMS-PCR).

Results: In this study, we observed that rs13429458 polymorphism was not associated with PCOS risk in two groups (P=0.42). On the other hand, data analysis indicated that the rs12478601 genotype significantly increased the risk of PCOS in the case group (P=0.032) in compared with control group. We found that the “T” allele of rs12478601 in the THADA gene had a significant relation to PCOS in the case group (odds ratio [OR]: 2.574, 95% confidence interval [CI]: 1.439-4.604, P=0.001).

Conclusion: This study has presented further evidence that TT and CT genotype of THADA rs12478601 is associated with a high risk of PCOS.

Keywords: Polycystic Ovarian Syndrome, Single Nucleotide Polymorphisms, THADA

Introduction

Polycystic ovarian syndrome (PCOS) is the most widespread endocrinopathy with a prevalence of 5-10% in the world (1). Also, clinical and/or biochemical hyperandrogenism and polycystic ovaries in ultrasound are considered as key characteristics of this syndrome (2). Despite of incomplete information about PCOS causes, it has indicated genetic factors are one of important factors (3). Several findings suggest that environmental factors, including enhanced caloric intake, endocrine disruptors, and lifestyle are involved in the pathogenesis of PCOS (4). Although there are studies that have emphasized the impact of hereditary factors, and relation to strong familial clustering (5, 6). Various studies have shown several genes involved in molecular pathways and mechanisms possibly linked to PCOS, including central energy metabolism, insulin secretion and action, gonadotropin action, and steroid hormone biosynthesis (7). DNA technology development brings knowledge of PCOS-related genetic factors (8). THADA (thyroid-associated protein) as a target gene in the thyroid tumor has been located on chromo-some band 2p21 which was determined first by Rippe et al. (9). THADA expression has been reported in the pancreas, thyroid, testes, thymus, adrenal medulla, adrenal cortex, small intestine, and stomach (10, 11). Because THADA is of fairly large size (370 kb) and was controlled by many regulatory elements, variants within THADA have been associated with a range of diseases (12). To explore possible relationships between single nucleotide polymorphism (SNP) and phenotypic variation, different computational tools like SNP Nexus, UTRscan, Human Splicing Finder (HSF), Repeat Masker and RNAsnp Web Server PupaSuite were used for prioritization of high-risk SNP in intronic and exonic 5' and 3'-untranslated region (UTR) SNPs.

These polymorphisms have been identified in the intronic region of THADA. The bioinformatics web tools, test SNPs with potential pathological results, to select markers for PCOS susceptibility.

SNPs within THADA have also been related to type 2 diabetes. Two SNPs of THADA, rs13429458 and rs12478601,
were determined to be related to PCOS (13). Based on previous studies, we tried to explore the association between these SNPs (rs13429458, rs12478601) and PCOS risk. This is a first study that investigating that this polymorphism among some of the Iranian female population.

Materials and Methods

Study design

This case-control study was contained 66 infertile women with PCOS history (patient group) and 44 healthy women without PCOS history (control group), who was attending Rooya Infertility Treatment Center of the Academic Center For Education, Culture, and Research (ACECR), Qom, Iran between January 2019 and October 2019. The Code of Ethics was IR.IAU.QOM.REC.1399.020.

Patients with PCOS were diagnosed according to the 2003 Rotterdam Criteria (The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004 (14, 15). Also, healthy women were invited to this study from whom having regular menstrual cycles that referred to our clinic because of other reasons such as a tubular problem or male factor infertility. Exclusion criteria included hyperinsulinemia, insulin resistance, another characteristic of hyperandrogenism, and obesity.

Demographics and clinical features assessment

All participants provided written informed consent and were asked not to change their daily physical activity and diet and not to take any new or additional pharmacotherapy within our research. Demographic information was self-reported and included height and body weight and body mass index (BMI) was calculated using the formula weight (kg)/height² (cm²). Infertility is defined as failure to establish a clinical pregnancy after 12 months of regular and unprotected sexual intercourse. For both groups, blood samples were taken on the morning of the second or third day of menstruation after overnight fasting of at least 12 hours. Peripheral blood sample was instantly centrifuged for 10 minutes at 3000 rpm (EBA20, Hettich, UK). To assess the hormonal profile of all participants, serum levels of follicle-stimulating hormone (FSH, DE1288), luteinizing hormone (LH, DE1289), prolactin (PRL, DE1291), estradiol (E2, LOT 1007843740), and Anti Mullerian Hormone (AMH, LOT 001-50-N488). These materials had been provided from Demeditec Diagnostics GmbH, Germany.

Single nucleotide polymorphisms genotyping

SNPs of the THADA gene with minor allele frequency (MAF) >0.05 were achieved from earlier published polymorphisms related to PCOS in the Hap Map Asian population (10, 13) and were applied to an initial screening. Peripheral blood (3 ml) was collected into EDTA-containing tubes and stored at -70°C until DNA extraction.

Using GeneAll Exgene TM Kit (105-101, GeneAll, South Korean), the DNA extraction process was performed in accordance with the relevant instructions. DNA purity and quantity were evaluated by NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, USA) at 260/280 nm. The quality of bands from DNA extracted was studied by agarose electrophoresis. Genotypes were identified by the amplification-refractory mutation system (ARMS) technique. To amplify the gene in specific SNPs, specific primers were designed using PRIMER1, a primer designed for tetra-primer amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). The characteristics of the primers, along with the length of the reproduced piece, are given in Table 1. Genotyping of rs13429458 (AA/AC/CC) and rs12478601 (CC/CT/TT) were performed by PCR with a sequence-specific primer (Table 1). The polymerase chain reaction was selected to amplify genomic DNA in a total volume of 20 μl reaction system. The polymerase chain reaction was selected to amplify genomic DNA with a volume of 20 μl reaction system: 2x Master Mix RED (Cat number: A190303, Ampliqon, Denmark) 10 μl, 2 μl of each primer (5 pmol/μL), 100 ng Genomic DNA and add ddH2O (Cat number: DW8505, Sina clon, Iran) up 20 μl. PCR was conducted as follows: initial denaturation at 95°C for 5 minutes, followed by 35 cycles consisting of 95°C denaturations for 30 seconds and 58°C annealing for the 40 seconds, and 72°C extension 40 seconds with a final extension of 5 minutes at 72°C. The amplification products were electrophoresed in 2% agarose gel at a voltage of 80 w for 45 minutes, also visualized under UV light using Ethidium bromide.

Table 1: Primer sequences of single nucleotide polymorphisms (rs13429458, and rs12478601)

| Primer sequences | Single nucleotide polymorphisms | Product size (bp) |
|------------------|---------------------------------|------------------|
| Inner primer (A allele) | F:GTCCTGTCAAAAGTTAGAAGATGAAAGCA | 208 |
| Inner primer (C allele) | R:GGCGGGTATAGGTGTATGTTATCGCTCTG | 286 |
| Outer primer (5’-3’) | F:TCAGCGGTATGATTTCGTAGTGGTTATT | 438 |
| Outer primer (5’-3’) | R:AAAGACTTTGAAGGCAATGTGATTCTTCT | 438 |
| Inner primer (C allele) | F:CATTTGCTGTCTTGGTTAGTACAAC | 180 |
| Inner primer (T allele) | R:AAAGCCCGGTTCTAACATTTATTTAAA | 220 |
| Outer primer (5’-3’) | F:CCAGTAAAAGACACATATTGGGCTGT | 343 |
| Outer primer (5’-3’) | R:TCCAACCTCGAATGTTGCTATTTAG | 343 |
Results

Demographic clinical characteristics

The mean age of the case group was 30.38 ± 5.086 years and the control group was 31.7 ± 5.262 years. The study of Infertility duration and BMI showed that there was a statistically significant difference means in both groups (P<0.05, Table 2).

Table 2: Comparison of baseline characteristics of study subjects in the PCOS and control groups

| Characteristics          | PCOS group | Control group | P value |
|--------------------------|------------|---------------|---------|
| Age (Y)                  | 30.38 ± 5.086 | 31.7 ± 5.262 | 0.202   |
| Infertility duration (Y) | 4.1 ± 0.2   | 1.1 ± 0.2     | 0.009*  |
| BMI (Kg/m²)              | 27.7 ± 4.841 | 25.71 ± 1.899 | 0.003*  |
| Smoking                  |             |               | 0.732   |
| Yes                      | 4           | 2             |         |
| No                       | 62          | 42            |         |
| Family history of diabetes |          |               | 0.09    |
| Yes                      | 39          | 16            |         |
| No                       | 27          | 28            |         |

BMI: Body mass index and PCOS: Polycystic ovarian syndrome.

Comparison of genotypic distributions and allele frequencies of SNPs rs13429458 and rs12478601

Genotype distributions and allele frequencies of SNPs, rs13429458 and rs12478601, in the two groups had been presented in Tables 4 and 5. Genotypic and OR were analyzed to evaluate the correlation between THADA gene polymorphisms and PCOS. Our results showed that rs13429458 did not significantly associated with PCOS risk in the control and PCOS groups. A second significant SNP (rs12478601) was determined by main model analysis (OR: 2.823, 95% CI: 1.22-6.533, P=0.014) and codominant model analysis (OR: 2.429, 95% CI: 0.998-5.913, P=0.032). At the allelic level, there was a significant difference between. The mutant allele frequency (allele T) increased in comparison to the control group (P=0.001). Subjects with the CT genotype or the TT genotype of THADA rs12478601 were at enhanced risk of undergoing PCOS.

Genotyping by tetra-primer ARMS-PCR

The tetra-primer ARMS-PCR method was successfully applied to genotyping selected SNPs (Fig.1).
### Table 4: Association of rs13429458 with PCOS risk based on logistic tests

| Genotype | PCOS group n (%) | Control group n (%) | P value | Adjusted OR | 95% CI          |
|----------|------------------|---------------------|---------|-------------|----------------|
| AA       | 32 (48.5)        | 26 (59.1)           | 0.42    | 1           |                |
| AC       | 26 (39.4)        | 12 (27.3)           | 0.568   | 0.568       | 0.241-1.339    |
| CC       | 8 (12.1)         | 6 (13.6)            | 0.923   | 0.284       | 0.284-2.999    |
| Allele   |                  |                     |         |             |                |
| A        | 90 (68.2)        | 64 (72.7)           | 0.471   | 0.804       | 0.443-1.457    |
| C        | 42 (31.8)        | 24 (27.3)           | 1.244   | 0.686       | 0.686-2.257    |
| Dominant |                  |                     |         |             |                |
| AA       | 32 (47.1)        | 26 (59.1)           | 0.568   | 0.241       | 0.241-1.339    |
| AC+CC    | 34 (52.9)        | 18 (40.9)           | 0.652   | 0.301       | 0.301-1.408    |
| Recessive|                  |                     |         |             |                |
| CC       | 8 (12.5)         | 6 (13.7)            | 0.815   | 1           |                |
| AC+AA    | 58 (87.5)        | 38 (86.3)           | 0.847   | 0.281       | 0.281-2.717    |
| Codominant|                |                     |         |             |                |
| AA       | 32 (48.5)        | 26 (59.1)           | 0.42    | 1           |                |
| AC       | 26 (39.4)        | 12 (27.3)           | 0.568   | 0.241       | 0.241-1.339    |
| CC       | 8 (12.1)         | 6 (13.6)            | 0.923   | 0.284       | 0.284-2.999    |
| Over dominant|            |                     |         |             |                |
| AA+CC    | 40 (60.1)        | 32 (72.8)           | 0.19    | 1           |                |
| AC       | 26 (39.9)        | 12 (27.2)           | 0.577   | 0.252       | 0.252-1.319    |

OR; Odds ratio, CI; Confidence interval, and PCOS; Polycystic ovarian syndrome.

### Table 5: Association of rs12478601 with PCOS risk based on logistic tests

| Genotype | PCOS group n (%) | Control group n (%) | P value | Adjusted OR | 95% CI          |
|----------|------------------|---------------------|---------|-------------|----------------|
| CC       | 14 (21.2)        | 19 (43.2)           | 0.032   | 1           |                |
| CT       | 34 (51.5)        | 19 (43.2)           | 0.596   | 0.202       | 0.202-1.758    |
| TT       | 18 (27.3)        | 6 (13.6)            | 2.429   | 0.998       | 0.998-5.913    |
| Allele   |                  |                     |         |             |                |
| C        | 62 (47)          | 57 (69.5)           | 0.001   | 0.388       | 0.217-0.695    |
| T        | 70 (53)          | 25 (30.5)           | 2.574   | 1.439       | 1.439-0.604    |
| Dominant |                  |                     |         |             |                |
| CC       | 14 (21.2)        | 19 (43.2)           | 0.014   | 2.823       | 1.22-6.533     |
| CT+TT    | 52 (78.8)        | 25 (53.8)           | 1       |              |                |
| Recessive|                  |                     |         |             |                |
| TT       | 18 (28)          | 6 (13.7)            | 0.752   | 1.188       | 0.409-3.447    |
| CT+CC    | 48 (72)          | 38 (86.3)           | 1       |              |                |
| Codominant|                |                     |         |             |                |
| CC       | 14 (14)          | 19 (43.2)           | 0.032   | 1           |                |
| CT       | 34 (34)          | 19 (43.2)           | 0.596   | 0.202       | 0.202-1.758    |
| TT       | 18 (18)          | 6 (13.6)            | 1.188   | 0.409       | 0.409-3.447    |
| Over dominant|            |                     |         |             |                |
| TT+CC    | 32 (32)          | 25 (56.8)           | 1       |              |                |
| CT       | 34 (34)          | 19 (43.2)           | 1.188   | 0.409       | 0.409-3.447    |

OR; Odds ratio, CI; Confidence interval, and PCOS; Polycystic ovarian syndrome.
Results of in silico tools

Data sets produced by ENCODE indicated that rs12478601 SNP is located at the H3K27Ac mark on seven cell lines. The variation occurs in the intronic position, which could lead to the alteration of an exonic splicing silencers (ESSs) element. UTRScan demonstrated that this region is located Upstream Open Reading Frame (uORF) that alteration can result in reducing translational efficiency. This SNP is located in the middle of the intron and most likely (score: 66.93) can create or destroy an ESS but making it hard to predict how this SNP might impact splicing. uORFs are essential gene expression regulatory elements. Besides, data have shown how uORF-mediated translational control can affect cell chance decisions.

Discussion

PCOS, a heterogeneous disorder, is considered a genetic base disease based on its distribution between twins and the accumulation of familial cases (18). A strong genetic basis for PCOS has been developed using multidisciplinary approaches including twin studies, transplants, candidate genes, which have paved the way for researchers to unravel the genetic underpinnings of PCOS etiology (19). THADA plays a role in diabetes and insulin sensitivity by observation of its altered methylation in the pancreatic islets of T2D patients, and the association of polymorphisms with altered B cell apoptosis and susceptibility to diabetes has been confirmed (20). Some of the SNP variations might influence mRNA expression and or alternative pre-mRNA splicing. Acetylation in K27 on histone H3 leads to open chromatin conformation which significantly increases gene expression (21). The results of the silica tool based on data sets produced by ENCODE indicated that this rs12478601 SNP is located at the H3K27Ac mark on seven cell lines. The variation occurs in the intronic position, which could lead to the alteration of an ESSs site or element (potential alteration of splicing). UTRScan demonstrated that the region is located uORF that its alteration can result in reducing translational efficiency. This SNP is located in the middle of the intron and most likely (score: 66.93) create or destroy an ESS. But it is difficult to predict how this SNP might affect splicing. uORFs are essential gene expression regulatory elements. Besides, data have shown how uORF-mediated translational control can affect cell chance decisions.

Previously, it was reported that these two SNPs (rs13429458 and rs12478601) of THADA are associated with PCOS (19). In this study, we investigated the polymorphisms of the THADA gene in some Iranian women population with PCOS for the first time. We found that rs12478601 is significantly associated with increased susceptibility to PCOS, while, rs13429458 was not associated with PCOS. Similarly, Goodarzi et al. (10), in their European cohort studies, identified no correlation between rs13429458 and risk of PCOS. Briefly, we identified a significant relationship between increased PCOS risk and the rs12478601 “T” allele of the THADA gene in some Iranian populations. Our results demonstrated that patients with the CT and TT genotype of THADA rs12478601 were at high risk of undergoing PCOS.

It has been presented those environmental factors are very important in the pathogenesis of PCOS. Obesity seems to be related to PCOS (22). For instance, in the United States, more than half of the patients with PCOS have overweight or obese. Increased adiposity is related to many dysfunctions of sex steroid metabolism, that may result in, increased androgen production and decreased SHBG (23). The impacts of BMI on PCOS were assessed in the study. The results showed that the BMI in the case group (27.7 ± 4.841 kg/m²) was significantly higher than in the control group 25.71 ± 1.899 kg/m²), and the risk of PCOS was even higher among obese women. Previous studies are consistent our finding. Our results showed that correlation between BMI and PCO presented similar to Greece and Spain population which is in agreement with that reported by Miazgowski et al. (24) and Li et al. (25), and Skiba et al. (26). PCOS is also related to impaired glucose tolerance (IGT) and increased insulin resistance and BMI (27). Women with PCOS had an increased prevalence of IGT, diabetic Mellitus, metabolic syndrome (28, 29). Our study also showed that in the PCOS women in the case group, FSH, LH, and LH/FSH ratio, and FBS had a significant increase in comparison with the control group. Quantitative trait analysis showed that there was a relationship between the rs2478601 genotype and enhanced levels of LH as well as a higher LH/FSH ratio in the PCOS patients. In the control group, LH, and LH/FSH ratios were detected to be increased in those with the rs2478601 genotype. In summary, we identified a significant association between increased PCOS risk and the rs12478601 “T” allele of the THADA gene in some Iranian populations. There is a need for more functional studies to confirm the correlation between the THADA gene and PCOS pathogenesis, especially with respect to different ethnicities. We predict that identification and characterization of additional PCOS susceptibility genes will ultimately provide more efficient strategies for the diagnosis, prevention, and treatment of PCOS in genetically heterogeneous populations.

Conclusion

These results showed that there is a relation between rs12478601 of the THADA gene and susceptibility to polycystic ovary syndrome, and allele T is a high-risk allele in this aim.

Acknowledgements

We would like to thank the Academic Center for Education, Culture and Research, Qom Branch, for financial supporting this research project. There is no conflict of interest in this study.

Authors’ Contributions

L.N., R.J., K.R., M.Kh., N.K.; Study design, data collection and, statistical analysis. L.N., R.J.; Sample
References

1. Albaghdadi AJH, Kan FWK. Therapeutic potentials of low-dose tacrolimus for aberrant endometrial features in polycystic ovary syndrome. Int J Mol Sci. 2021; 22(6): 2872.

2. Zhang FF, Zhang Q, Wang YL, Wang FF, Hardiman PJ, Qu F. Intergenerational influences between maternal polycystic ovarian syndrome and offspring: an updated overview. J Pediatr. 2021; 232: 272-281.

3. Crespo RP, Bachega TASS, Mendonça BB, Gomes LG. An update of genetic basis of PCOS pathogenesis. Arch Endocrinol Metab. 2018; 62(3): 352-361.

4. Hejnlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. Dan Med J. 2014; 61(7): B4890.

5. Mykyhalchenko K, Lizeneva D, Trofimova T, Walker W, Suturina L, Diamond MP, et al. Genetics of polycystic ovary syndrome. Expert Rev Mol Diagn. 2017; 17(7): 723-733.

6. Xia JY, Tian W, Yin GH, Yan H. Association of Rs13405728, Rs12478601, and Rs2479106 single nucleotide polymorphisms and in vitro fertilization and embryo transfer efficacy in patients with polycystic ovarian syndrome: a case control genome-wide association study. Kaohsiung J Med Sci. 2019; 35(1): 49-55.

7. Dumesic DA, Hoyos LR, Chazenbalk GD, Naik R, Padmanabhan B, Abbott DH. Mechanisms of intergenerational transmission of polycystic ovary syndrome. Reproduction. 2020; 159(1): R1-R13.

8. Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): current perspectives. Appl Clin Genet. 2019; 12: 249-260.

9. Rippe V, Drieschner N, Meiboom M, Escobar HM, Bonk U, Belge G, et al. Identification of a gene rearranged by Zp21 aberrations in thyroid adenosmas. Oncogene. 2003; 22(38): 6111-6114.

10. Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, Chen YD, et al. Replication of association of DENND1A and THADA variants with polycystic ovarian syndrome in European cohorts. J Med Genet. 2012; 49(2): 90-95.

11. Gao J, Xue JD, Li ZC, Zhou L, Chen C. The association of DENND1A gene polymorphisms and polycystic ovary syndrome risk: a systematic review and meta-analysis. Arch Gynecol Obstet. 2016; 294(5): 1073-1080.

12. Ha L, Shi Y, Zhao J, Li T, Chen ZJ. Association study between polycystic ovarian syndrome and the susceptibility genes polymorphisms in Hui Chinese women. PLoS One. 2015; 10(5): e0126505.

13. Bao S, Ren YC, Chen ZS, Yang SY, Yi YP, Li JJ, et al. THADA gene variants and polycystic ovarian syndrome in a Hainan Chinese population. Int J Clin Exp Pathol. 2016; 9(11): 11883-11889.

14. Wang R, Mol BWJ. The rotterdam criteria for polycystic ovarian syndrome: evidence-based criteria? Hum Reprod. 2017; 32(2): 261-264.

15. Naserpoor L, Berjis K, Jannatifar R. Evaluation of the pregnancy rate of freezing embryo transfer in the presence or absence of GnRh agonist. J Arak Univ Med Sci. 2020; 23(6): 818-827.

16. Pesole G, Liuni S, Grillo G, Lucchiari F, Mignone F, Gissi G, et al. UTRdb and UTRsite: specialized databases of sequences and functional elements of 5’ and 3’ untranslated regions of eukaryotic mRNAs. Update 2002. Nucleic Acids Res. 2002; 30(1): 335-340.

17. Frixione E, Ruiz-Zamarrapa L. The 'scientific catastrophe' in nucleic acids research that boosted molecular biology. J Biol Chem. 2019; 294(7): 2249-2256.

18. Maleki A, Bashirian S, Soltanian AR, Jenabi E, Farhadinasab A. Association between polycystic ovary syndrome and risk of attention-deficit/hyperactivity disorder in offspring: a meta-analysis. Clin Exp Pediatr. 2021; 37(6): 716-720.

19. Dadachanji R, Sawant D, Patil A, Mukherjee S. Replication study of THADA rs13429458 variant with PCOS susceptibility and its related traits in Indian women. Gynecol Endocrinol. 2021; 37(8): 716-720.

20. Ankoglu H, Erkoc-Kaya D, Ipekci SH, Gicoglu F, Korez MK, et al. Type 2 diabetes is associated with the MTNR1B gene, a genetic bridge between circadian rhythm and glucose metabolism, in a Turkish population. Mol Biol Rep. 2021; 48(5): 4181-4189.

21. Carnesecchi J, Pinto PB, Lohmann I. Hox transcription factors: an overview of multi-step regulators of gene expression. Int J Dev Biol. 2018; 62(11-12): 733-732.

22. Artini PG, Obino MER, Micelli E, Malacarne E, Vacca C, Papini F, et al. Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women. Gynecol Endocrinol. 2020; 36(9): 755-759.

23. Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol. 2021; 15(3): 790-800.

24. Miazgowski T, Martopullo I, Widecka J, Miazgowski B, Brodowska A. National and regional trends in the prevalence of polycystic ovary syndrome since 1990 within Europe: the modeled estimates from the Global Burden of Disease Study 2016. Arch Med Sci. 2019; 17(2): 343-351.

25. Li H, He YL, Li R, Wong C, Sy B, Lam CW, et al. Age-specific reference ranges of serum anti-müllerian hormone in healthy reference women and its application in diagnosis of polycystic ovary syndrome. BJOG. 2020; 127(6): 720-728.

26. Skiba MA, Bell RJ, Herbert D, Garcia AM, Islam RM, Davis SR. Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study. Hum Reprod. 2021; 36(6): 1611-1620.

27. Ali AH, Abbas HJ, Naser NA. Preptin and adropin levels as new biomarkers of prediabetes to type 2 diabetes mellitus in women with polycystic ovary syndrome: a population study. Gynecol Endocrinol. 2021; 37(8): 716-720.

28. Maleki A, Bashirian S, Soltanian AR, Jenabi E, Farhadinasab A. Association between polycystic ovary syndrome and risk of attention-deficit/hyperactivity disorder in offspring: a meta-analysis. Clin Exp Pediatr. 2021; 37(6): 716-720.